Fulgent Genetics (FLGT) Stock Price Slides As Losses Deepen Guidance Falls

Fulgent Genetics came into this print on a rough streak, with the stock already down over the past month, and the earnings release has hit sentiment hard. Shares fell about 18% to US$16.55 as investors reacted to another quarter of sizeable losses and lower full year guidance.

The core story this time is margin and profit pressure. Fulgent Genetics posted a quarterly net loss of US$29.5m on US$85.4m of revenue and now expects a full year non GAAP loss per share in the low US$2 range. The market clearly moved to reprice that reality in one session.

Is Fulgent Genetics now priced for a long grind of losses, or has the selloff pushed NasdaqGM:FLGT into genuine bargain territory on sales multiples? Compare the stock against peers in our valuation analysis for Fulgent Genetics.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$85.4m vs. US$81.8m (up roughly 4%)
• Net Loss (Q2 2026 vs Q2 2025): US$29.5m loss vs. US$19.0m loss (loss widened about 56%)
• Basic EPS (Q2 2026 vs Q2 2025): loss of US$1.05 per share vs. loss of US$0.62 per share (loss per share increased about 70%)
• GAAP Gross Margin (Q2 2026): 30.1%, with non GAAP gross margin at 31.3%

If you are tired of reading another wall of earnings headlines and raw figures on Fulgent Genetics without a clear picture of what it all means for the business, get a clear visual overview of the company, including a full view of its loss profile and broader financial picture, in the company report for Fulgent Genetics.

Fulgent Genetics bull case meets mixed execution

The optimistic view on Fulgent Genetics is that broader clinical guideline support, CE Mark progress and expanded managed care coverage will steadily lift test volumes, while lab automation and bioinformatics work improve margins. The latest quarter offers only partial support. Revenue rose 4% year on year with a 20% sequential lift helped by the Bako Diagnostics and StrataDX integration, and Anatomic Pathology revenue grew strongly on that acquisition. However, Precision Diagnostics revenue fell year on year and non GAAP gross margin sat at 31.3%, which is below the mid 30% range targeted for the full year. Management still talks about AI pathology tools, whole genome enhancements and RNA integration, but the widened non GAAP loss of about US$16.2m and full year loss guidance around the low US$2 range indicate that profitability milestones have not yet followed the commercial wins.

Bear case on margins and cash burn gains traction

The bear argument focuses on persistent operating losses, uncertain margin recovery and execution risk around new platforms and international expansion. This quarter largely supports those concerns. GAAP net loss widened to US$29.5m and adjusted EBITDA stayed in the red at about US$17.1m. Management cut 2026 revenue guidance to US$330m to US$340m and now expects a non GAAP loss of US$2.22 to US$2.35 per share, with non GAAP operating margin in the mid minus 20s. Precision Diagnostics revenue declined year on year and the largest customer is reducing volumes as testing moves in house. Reported gross margin of 30.1% was pressured by a billing system transition that depressed collections, and a US$13.5m legal settlement plus intangible impairment weighed on cash. The strong US$551.5m cash position helps, but bears focused on prolonged losses and slower margin progress are seeing several of their milestones hit.

After widening losses, lower guidance and a billing transition that already hit reported margin, it is fair to ask whether Fulgent Genetics is facing isolated setbacks or something more structural. Review the independent risk analysis for Fulgent Genetics which shows 1 important warning sign

Take Control Of Your Next Move

If the widening losses and guidance reset at Fulgent Genetics have your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and keep on top of the most important updates across all your holdings. For longer term conviction, tap into crowd wisdom and see how other investors are thinking through the same risks and potential catalysts in the Community. Spot emerging opportunities and red flags early so you can stay ahead of the market instead of reacting to it.

Seeking Alternatives Beyond Fulgent Genetics

Markets move fast and the next breakout stocks rarely wait around. Tap into fresh ideas with real momentum while they are still under the radar for now and act now.

• Spot resilient compounders before momentum takes off by scanning the 81 resilient stocks with low risk scores that aim to hold up when sentiment turns and keep portfolios from getting caught in sharp drawdowns.
• Chase early strength in digital infrastructure by reviewing the curated 57 AI infrastructure stocks packed with companies positioned around surging data needs and AI workloads while it still matters.
• Ride potential income and price swings together by checking the hand picked 9 dividend fortresses that may offer hefty yields while prices remain anchored for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com